Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

This study found that the TYK2 inhibitor deucravacitinib did not significantly improve hair regrowth in patients with alopecia areata compared to placebo, suggesting it may not be effective for this condition. No new safety issues were identified.

In this randomized trial, bicalutamide was found to improve hair count and shaft diameter more than spironolactone in women with Female Pattern Hair Loss over 24 weeks, although no significant differences were observed in clinical endpoints between the two treatments.

This study found that treatment with human foreskin fibroblast conditioned medium improved both objective measures like hair density and subjective satisfaction in patients with androgenetic alopecia.

This study found that in patients with female androgenetic alopecia, mesodermal injection of 0.5% minoxidil was more effective in increasing hair density and improving hairline height than topical 2% minoxidil, with comparable safety over 16 weeks.

This study found that combining ablative fractional CO2 laser treatment with topical minoxidil significantly improved frontal hairline regrowth and patient satisfaction in men with androgenetic alopecia compared to using minoxidil alone, without serious adverse effects.

This registered trial will investigate whether preoperative botulinum toxin can improve hair transplantation outcomes by enhancing blood flow and reducing ischemia in the scalp.

In this open-label study of post-menopausal women with frontal fibrosing alopecia, researchers found that 12 weeks of baricitinib monotherapy significantly reduced disease activity as measured by the Lichen Planopilaris Activity Index, improved patient-reported scalp hair growth, but showed no significant change in eyebrow growth.

This phase 3 trial found that over 50% of adolescents with severe alopecia areata achieved successful hair regrowth after 52 weeks on baricitinib 4-mg, with no new safety concerns reported compared to existing safety profiles.

In this study, nearly one-third of patients with severe alopecia areata treated with ritlecitinib achieved complete scalp hair regrowth at least once over three years, and most maintained regrowth or stayed at low hair loss levels subsequently.

This clinical study found that a three-month Ayurvedic leave-on treatment significantly improved hair density and reduced hair fall in healthy Indian adults experiencing hair loss, with efficacy supported by increased VEGF expression in dermal papilla cells, promoting follicular angiogenesis.

This randomized controlled trial reported that combining oral Biotin supplements with PRP offered no additional benefits for hair regrowth in patients with Androgenetic Alopecia compared to PRP alone.

This study found that combining Fractional Microneedling Radiofrequency (FMRF) with topical minoxidil significantly increased hair counts and density more than minoxidil alone or combined with Fractional CO2 in women with androgenic alopecia.

This study found that both PRP injections and microneedling treatments significantly improved hair count and thickness in patients with androgenetic alopecia, without significant differences between the two methods. Microneedling also enhanced patient satisfaction and treatment tolerance.

In this randomized controlled trial, the combination of Bhringaraja Taila Shiroabhyanga and Yastimadhuka Taila Nasya was found to significantly improve hair density, reduce hair fall, and decrease scalp visibility in females with Khalitya compared to Nasya alone, with no reported adverse effects.

In this study, both methotrexate gel and betamethasone lotion were found to be effective and safe treatments for localized alopecia areata, with similar overall response rates. However, methotrexate gel had a higher incidence of local side effects, such as irritant dermatitis and itching.

This study reported that ritlecitinib was generally well tolerated over 72 months in patients aged 12 and older with alopecia areata, with adverse events like headache and nasopharyngitis observed, and safety outcomes consistent with previous studies.

This study compared oral tofacitinib and methotrexate in treating moderate-to-severe alopecia areata, finding that tofacitinib was more effective at reducing SALT scores and improving scalp hair assessment PRO scores, though both treatments reduced psychological distress similarly without serious adverse effects.

This study found that both tofacitinib and methotrexate effectively reduced hair loss and psychological distress in patients with moderate-to-severe alopecia areata, but tofacitinib showed much greater efficacy. Both treatments had similar safety profiles, with no serious adverse effects reported.

The study did not find evidence to support using botulinum toxin as a treatment for androgenetic alopecia.

This study found that vitamin D supplementation significantly improved clinical pregnancy rates in women with polycystic ovary syndrome treated at a Turkish infertility clinic, though it did not affect live birth or miscarriage rates.

The combination of finasteride and minoxidil is as safe and effective as minoxidil alone for improving hair growth in men.

In this study using C57BL/6 mice, the researchers observed that combining minoxidil with exosomes and DNA polynucleotides improved hair follicle density and promoted gene expression linked to hair growth, suggesting enhanced hair growth potential over minoxidil alone.

This study found that BCG injection in COVID-19 convalescent adults reduced long COVID symptoms like hearing and cognitive issues but also led to increased hair loss in women at six months.

In this clinical trial, adding topical calcipotriol to intralesional triamcinolone acetonide significantly increased hair regrowth efficacy in scalp alopecia areata patches compared to steroids alone, but not in beard patches, with a lower incidence of atrophy observed.

This study compared two PRP preparation techniques for treating androgenetic alopecia and found that both methods led to some improvement in hair loss, but further research is suggested due to variations in PRP preparation.

This study evaluated microneedling's effect on hair loss, finding a minor reduction in SALT scores for androgenetic alopecia patients, but no significant change for fibrosing or alopecia areata groups. Further skin biopsy analyses are pending to explore other changes beyond SALT scores.

This study compared auriculotherapy, Aslagh capsule, and metformin in women with PCOS, finding auriculotherapy significantly improved menstrual cycle duration and excess hair growth more than the other treatments, though all reduced these symptoms.

This study found that a combination of probiotic strains of Lactiplantibacillus administered over 16 weeks reduced the number and density of telogen hairs in individuals with androgenic alopecia, while increasing the abundance of Lactobacillus in their gut microbiota.

This study concluded that adding 5% topical Procapil to PRP therapy provided better outcomes for androgenetic alopecia than PRP alone, as assessed by dermatologist evaluations and patient satisfaction.

This study found that low-level light therapy was as effective as 5% minoxidil for increasing hair density in men with androgenetic alopecia over six months.